http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112015026298-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aeee8d3f65d495ab7c77f7132d3b5da2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0036 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2014-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dcc887ca070356a387d9a26beacef7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d78a60d1aaae84f76da3a88855d0a60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adad670e5753fc5b102f8a172269b76c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_387e6666aa6cd3b49b71db7dea11e546 |
| publicationDate | 2017-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112015026298-A2 |
| titleOfInvention | dispensing vehicle, methods for providing an individual's plasma aromatase inhibitor, for synchronizing ovulation, for inducing superovulation, for improving fertility, for inducing double ovulation, and for enhancing twin formation in a mammal, use of a dispensing vehicle, a luteolytic dose of a prostaglandin, and an ovulatory dose, and kit for providing a mammalian plasma aromatase inhibitor |
| abstract | 1/2 summary “Dispensing vehicle, methods to provide an individual's plasma aromatase inhibitor, to synchronize ovulation, to induce superovulation, to improve fertility, to induce double ovulation and to improve twin formation in a mammal, use of a dispensing vehicle, a luteological dose of a prostaglandin, and an ovulatory dose A kit for providing an aromatase inhibitor in a mammalian plasma is described herein as an intravaginal device that provides biologically active circulating concentrations of an aromatase inhibitor for at least about 4 days. Three estradiol inhibitory compounds (letrozole, anastrozole and fenbendazole) were tested in vitro using bovine granular cell culture. Letrozole has been found to be the most efficient and potent inhibitor. Liposome-based and one wax-based formulations were used to evaluate the diffusion of letrozole through the bovine vaginal mucosa in a diffusion chamber study. The samples were collected within 24 hours. The wax-based vehicle was selected for further development of an intravaginal letrozole device based on its fixed dispensing rate. In an in vivo study in cattle, 3 different intravaginal devices containing 3 g of letrozole were tested: wax (with 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, dope) + gel coating (n = 2), wax + gel coating (n = 4) and wax (n = 4). Blood samples were collected serially from time 0 to 120 hours, and daily thereafter to measure circulating concentrations of letrozole by lc / ms / ms. Addition of a letrozole-containing gel coating improved initial absorption and accelerated increase in plasma concentrations of the active ingredient, while the letrozole-containing 2/2 wax-based vehicle maintained prolonged release from the intravaginal device. |
| priorityDate | 2013-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.